Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22057298 | 0.88 | CETP (0.46) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL23095166 | 0.84 | CETP (0.48) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL14402392 | 0.83 | CETP (0.58) | CETPCHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL13849933 | 0.83 | CETP (0.58) | CETPCHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL13849901 | 0.83 | CETP (0.58) | CETPCHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL14402454 | 0.81 | CETP (0.55) | CETPCHRM2CHRM1CHRM3 | |
| SCHEMBL18896317 | 0.81 | CETP (0.48) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL2662597 | 0.79 | CETP (0.51) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL22849934 | 0.78 | CETP (0.47) | CETPCHRM2CHRM1CHRM3CARM1 | |
| SCHEMBL178310 | 0.78 | CHRM2 (0.55) | CETPCHRM2CHRM1CHRM3CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-03-30 | — | — | US | disclosed |
| US-20200172542-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961242-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | CETP 60/4885CHRM2 1892/4885CHRM1 2161/4885 |
| US-20200172542-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, LPCAT1, PLA2G10 | CETP 58/4885CHRM2 2001/4885CHRM1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.